Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cevostamab - Genentech

Drug Profile

Cevostamab - Genentech

Alternative Names: BFCR-4350A; RG 6160; RO-7187797

Latest Information Update: 30 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Roche
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 09 Dec 2023 Pharmacodynamics data from a phase I trial in multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 25 Jul 2023 Genentech initiates enrolment in a phase I trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia and South Korea (IV, Infusion) (NCT05927571) (EudraCT2022-501724-15-00)
  • 03 Jul 2023 Genentech plans a phase I trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) (IV), in July 2023 (NCT05927571) (EudraCT2022-501724-15-00)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top